Artwork

Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Integrating New Data From AIDS 2024: Pharmacist Perspectives

18:22
 
Del
 

Manage episode 437172754 series 2884624
Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

  • The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
  • An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
  • 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
  • A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

See the full program here.

  continue reading

407 episoder

Artwork
iconDel
 
Manage episode 437172754 series 2884624
Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

  • The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
  • An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
  • 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
  • A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

See the full program here.

  continue reading

407 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett